The T790M mutation mostly appears in EGFR-mutated NSCLC with acquired resistance to first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) and accounts for the majority of acquired resistance mechanisms to first- and second-generation EGFR-TKIs (40–60%) [4–6]. Here, EGFR is linked to non-small cell lung carcinoma.